Sabiia Seb
PortuguêsEspañolEnglish
Embrapa
        Busca avançada

Botão Atualizar


Botão Atualizar

Ordenar por: 

RelevânciaAutorTítuloAnoImprime registros no formato resumido
Registros recuperados: 1
Primeira ... 1 ... Última
Imagem não selecionada

Imprime registro no formato completo
Candesartan, rather than losartan, improves motor dysfunction in thioacetamide-induced chronic liver failure in rats BJMBR
Murad,H.A.; Gazzaz,Z.J.; Ali,S.S.; Ibraheem,M.S..
Minimal hepatic encephalopathy is more common than the acute syndrome. Losartan, the first angiotensin-II receptor blocker (ARB), and candesartan, another widely-used ARB, have protected against developing fibrogenesis, but there is no clear data about their curative antifibrotic effects. The current study was designed to examine their effects in an already-established model of hepatic fibrosis and also their effects on the associated motor dysfunction. Low-grade chronic liver failure (CLF) was induced in 3-month old Sprague-Dawley male rats using thioacetamide (TAA, 50 mg·kg−1·day−1) intraperitoneally for 2 weeks. The TAA-CLF rats were randomly divided into five groups (n=8) treated orally for 14 days (mg·kg−1·day−1) as follows: TAA (distilled water),...
Tipo: Info:eu-repo/semantics/article Palavras-chave: Candesartan; Hepatic fibrosis; Liver failure; Losartan; Motor dysfunction; Thioacetamide.
Ano: 2017 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2017001100611
Registros recuperados: 1
Primeira ... 1 ... Última